cyrilzakka/clinical-trials huggingface dataset:
Hypertension Management in Family Practice

High blood pressure is the greatest threat to the global burden of disease, contributing to an estimated 9.4 million deaths a year. Cardiovascular disease morbidity and mortality are positively correlated with the degree of elevation of blood pressure, without any evidence of a threshold down to at least 115/75 mm Hg\[2\]. Hypertension is common, and nearly every clinician in every specialty deals either directly or indirectly with managing it or its consequences.

The population age 65 years or older numbered 46.2 million in 2014 and they represent 14.5% of the US population, the older population in 2030 is projected to be more than twice as large as in 2000, growing from 35 million to 74 million and representing 21 percent of the total U.S. population and it is expected to more than double to 98 million in 2060.Proper managing and controlling blood pressure markedly improves patient morbidity and mortality, SHEP study showed that in persons aged 60 years and over with isolated systolic hypertension, antihypertensive stepped-care drug treatment with low-dose chlorthalidone as step 1 medication reduced the incidence of total stroke by 36%.This study will estimate the prevalence of hypertension diagnosis, treatment and outcomes in a Family Practice population. It is a hypothesis generating study

This a retrospective cross-sectional chart review study. The study population will consist of a random sample of patients from the Family Practice of the LSU Department of Family Medicine at LSU Health Sciences Center in New Orleans (LSUHSC-NO) Chart data will be collected retrospectively back to one year from date of starting data abstraction.

Data Quality The data used in this study comes from patient charts that are actively being used in the management of patient care. Data quality will be ensured through several means. First, the data collection process will be conducted family medicine resident. Second, data will be abstracted directly into an electronic encrypted Excel file.

Selection of Participants The family medicine residents will take each one 25 patients each and review the charts and record the information on an Excel spread sheet.

Eligibility Criteria:
Inclusion Criteria

* hypertension

Exclusion Criteria:

* No hypertension
Raltegravir vs. Atazanavir in Combination With Truvada® for the Treatment of Antiretroviral naïve HIV Infected Patients

This is a pilot that will evaluate two regimens for treating HIV infected patients that haven't been on treatment before. HIV/AIDS patients may have an increased risk of myocardial infarction and antiretroviral therapy used may contribute to this. We will evaluate virological, immunological and cardiovascular effects of two HIV treatment regimens.

We will check blood studies used to evaluate HIV patients response to therapy including CD4 count and HIV viral load test. We will check routine safety labs done on HIV patients and also check homocysteine levels and creatine kinase level. We will evaluate homocysteine and IL6 levels at baseline, week 48, and week 96.

Eligibility Criteria:
Inclusion Criteria:

* Patients must be HIV-1 positive and naïve to HIV therapy.
* Patients must plan to participate and be available for the trial for the 96-week study period.
* Patients followed at Thomas Street Clinic.
* Patients must be over 18 years old.

Exclusion Criteria:

* Patients must not be pregnant or plan to become pregnant over the 96-week study period.
* Patients cannot be on a proton pump inhibitor.
* Patients cannot be undergoing treatment for active tuberculosis.
* Renal Insufficiency with a creatinine clearance \< 50 ml/min/1.73 m2 by the MDRD GFR calculation.
Study the Relationship Between Obesity and Hepatitis C Replication

Patients with chronic hepatitis C viral infection (HCV) and with a BMI greater than 25Kg/m2 are refractory to medical treatment. Also, HCV replication seems to be affected when modeling insulin resistance in replicon cell culture systems.

PPARg -agonist (Pioglitazone) is effective in controlling liver inflammation in obese subjects with non-alcoholic steatohepatitis (NASH) and also improving insulin sensitivity. Therefore, we hypothesize that improving insulin resistance and /or inflammation may affect HCV replication and viral kinetics. Independently of PPARg pathways, Prednisone may increase HCV viral kinetics. .

This is a randomized, two arm clinical trial. The investigators performing the primary and secondary endpoints are blinded to subject identifiers and arm identifiers.

Subject's screening for HCV Genotype 4 started in Agouza Hospital in July 2010 and ended in February, 2011. No recruitment has occurred for HCV Genotype 1.

Eligibility Criteria:
Inclusion Criteria:

* Infection with HCV genotype 1 or 4 (subjects infected with multiple genotypes are not eligible)
* BMI greater than 25 Kg/m2
* HCV-infected subjects naïve to treatment: subjects who either have never been treated for HCV infection or who previously received HCV treatment ending more than 3 months prior to enrollment for not longer than 2 weeks
* Plasma HCV RNA concentration of \>10,000 IU/mL at the screening evaluation

Exclusion Criteria:

* Previous intolerance to Pioglitazone, Rosiglitazone, Troglitazone or corticosteroids
* Women who are pregnant or breastfeeding
* History of diabetes mellitus requiring treatment other than diet
* Decompensated liver disease or other known causes of liver disease including, but not limited to autoimmune hepatitis, Wilson's disease, hemochromatosis, primary biliary cirrhosis, schistosomiasis, sclerosing cholangitis, alcohol- or drug-induced liver disease, or alpha-one antitrypsin deficiency
* Concurrent hepatitis B virus (HBV) infection
* Known immunodeficiency disease, autoimmune disorders or active gastrointestinal disease
* Abuse of alcohol or illicit drugs within 6 months before enrollment
* Use of an investigational drug within 4 weeks before the screening visit or during the screening period.
* Use of systemic immunosuppressants
* History of poorly controlled psychiatric disease or poorly controlled pulmonary disease
Vasoconstriction Trial With LEO 90100 Aerosol Foam

Vasoconstriction study with LEO 90100

This study compares the pharmacodynamic activity of LEO 90100 with Dermovate cream, Diprosone ointment, Elocon cream, Locoid ointment and LEO 90100 vehicle using a human skin blanching test

Eligibility Criteria:
Inclusion Criteria:

* Subjects demonstrating adequate vasoconstriction to Diprosone® ointment within 15 days prior to dosing (unoccluded application of Diprosone® ointment for 4-6 hours must show a visual score of skin blanching of at least one unit (visual scale (0-4)).
* Subjects without signs of skin irritation/disease/disorders/symptoms or blemishes on test sites (e.g. erythema, dryness, roughness, scaling, scars, moles, sunburn).

Exclusion Criteria:

* Abnormal pigmentation of the skin or skin type that could, in any way, confound interpretation of the trial results (skin type V and VI on the Fitzpatrick scale).
* Female subjects who are breastfeeding.
Effect of Solution-Focused Approach on the Internet,Social Media Addiction and Self-Efficacy Levels OfNursing Students

The purpose of this research; is to determine the effect of solution-oriented approach on internet, social media addiction and self-efficacy levels of nursing students.

A pretest-posttest randomized controlled experimental design will be used in the research.

The research will be carried out between 4 April 2022 and 28 April 2023 at Sivas Cumhuriyet University . Personal Information Form, Internet Addiction Scale, Social Media Addiction Scale and Self-Efficacy Competence Scale were applied to a total of 1057 nursing students who were continuing their education in the 1st, 2nd and 3rd years at the Faculty of Health Sciences (683) and Suşehri Health College (374), where the research would be conducted.Since the final data of the study will be received next year, students in the 1st, 2nd and 3rd grades will be included in the interviews in order to prevent data loss, and 4th graders will be excluded from the study.

Eligibility Criteria:
Inclusion Criteria:

* Being between the ages of 18-25,
* 67 \< Internet Addiction Scale (IAS) Score \< 109,
* 73 \< Social Media Addiction (SMDS) Score \< 140.

Exclusion Criteria:

* Receiving any psychological counseling and treatment,
* Being closed to communication,
* To have extended the term,
* Not volunteering to participate in the research.
Seizure Prevention in Traumatic Brain Injury With Levetiracetam and Lacosamide

The purpose of this study is to assess the incidence of early post-traumatic seizures. The study will also assess the benefit of lacosamide compared to levetiracetam in regards to agitation and behavioral adverse effects in patients with moderate to severe traumatic brain injury requiring seizure prophylaxis.

This is a prospective randomized controlled trial of patients with moderate to severe TBI requiring seizure prophylaxis to prevent early and late posttraumatic seizures. Patients will be identified and randomized as soon as possible, within 24 hours, from injury and started on seizure prophylaxis if they meet the predefined inclusion and exclusion criteria. Patients randomized to the levetiracetam group will receive levetiracetam 1000 mg intravenously or by mouth twice daily for a total of 7 days. Patients randomized to the lacosamide group will receive lacosamide 200 mg intravenously or by mouth twice daily for a total of 7 days.

Eligibility Criteria:
Inclusion Criteria:

* 18 years and older
* Diagnosis of moderate to severe traumatic brain injury
* Seizure prophylaxis with one of the two study drugs within 24 hours of initial injury
* Patients admitted into the trauma team service

Exclusion Criteria:

* Patients on anti-seizure or anti-epileptic medication
* History of seizures, witnessed or activity of seizure before prophylaxis medication started
* Received anti-seizure medication before randomized into the study
* Patients with a history of alcohol withdrawal or experiencing alcohol withdrawal that require medication treatment
* Spinal cord injury, history of bradycardia or permanent pacemaker, end stage renal disease
* Transferred form an outside hospital \>24 hours from injury and/or given or unconfirmed anti-seizure medication at other hospital
* Death, withdrawal of life support or transfer to hospice within 24 hours of injury
* Special population (pregnant, incarcerated)
* Informed consent not obtained within 72 hours from injury
STroke Secondary Prevention With Catheter ABLation and EDoxaban for Patients With Non-valvular Atrial Fibrillation: STABLED Study

Catheter ablation (CA) has been reported to reduce risk of stroke in patients with nonvalvular atrial fibrillation (NVAF) in retrospective studies, but risk and benefit of CA has not been well elucidated in NVAF with recent cerebral infarction in prospective randomized trials.

In patients with NVAF, stroke is an independent risk factor for a subsequent cerebral infarction. Although anticoagulant therapy can effectively reduce thromboembolic events, the reported annual recurrence rate in NVAF and previous stroke patients in the "real-world" is not low even with appropriate antithrombotic treatment; 8.6% in patients with "guideline adherent" antithrombotic therapy and around 5% in patients treated with anticoagulant therapy. NVAF and recent stroke is high-risk population for stroke recurrence even with anticoagulant therapy, and developing optimal secondary prevention strategy is an urgent task.

Catheter ablation (CA) is now widely used to treat symptoms related to NVAF. Some retrospective studies showed a beneficial effect of CA for stroke prevention using age-/sex-matching or propensity-score matching. Moreover, CA have a potential to improve survival or prevent heart failure development in patients with AF. However, the effect of CA for secondary stroke prevention or impact of CA for NVAF patients with recent ischemic stroke for survival or developing heart failure has not been evaluated in a prospective randomized trial. Therefore, in the present study, we intend to compare two groups of patients with NVAF with a history of cerebral infarction: a group receiving standard medical therapy (control group) and a group receiving standard medical therapy plus CA (CA group).

Eligibility Criteria:
Inclusion Criteria:

* Age ≥20 or ≤85 years at time of giving informed consent
* Nonvalvular atrial fibrillation
* History of stroke in previous 6 months
* Current or planned treatment with edoxaban
* Modified Rankin scale ≤3

Exclusion Criteria:

* Symptomatic paroxysmal AF resistant to anti-arrhythmic drugs
* Presence of left atrial thrombus and left atrial appendage on transthoracic echocardiography, computed tomography or magnetic resonance imaging
* Unable to take anticoagulation therapy for any reason, including tendency to bleed or considered at high risk for bleeding from anticoagulation therapy.
* Presence of severe renal disorder (estimated creatinine clearance \<30 mL/min by Cockroft-Gault equation)
* Previous CA or surgical intervention for AF
* History of treatment with a left atrial appendage closure device
* Left atrial diameter ≥55 mm on transthoracic echocardiography
* Ejection fraction ≤35% on transthoracic echocardiography
* Persistent AF for ≥10 years
* Pregnant or possibility of pregnancy
* Unlikely to complete the study, such as due to progressive malignant tumor
* Participating or planning to participate in another clinical trial
* Unwilling to participates
* Judged as incompatible for the study by the investigators
Voice Analysis in Patients With Neurologic Diseases

In this observational pilot study, the investigators will record and assess voice samples from healthy participants and those participants affected by neurologic diseases to evaluate possible differences in voice features.

In this study, the investigators will evaluate the clinical features of healthy participants and those participants with neurologic disorders by applying dedicated clinical scales. Also, the investigators will assess voice impairment by using perceptual examination tools. Then, the investigators will apply spectral analysis to assess the main frequency components of voice in healthy participants and in patients affected by neurologic disorders with a prominent voice impairment. To distinguish between healthy participants and patients affected by various neurologic diseases, the investigators will apply a voice analysis based on support vector machine (SVM) classifier that included a large number of features in addition to the main frequency components of voice.

For these purposes, the investigators will assess in detail the sensitivity, specificity, positive predictive value, and negative predictive value and accuracy of all diagnostic tests. Furthermore, the investigators will calculate the area under the receiver operating characteristic (ROC) curves to verify the optimal diagnostic threshold as reflected by the associated criterion (Ass. Crit.) and Youden Index (YI). To assess possible clinical-instrumental correlations, the investigators will also use a modified algorithm of SVM analysis to calculate a continuous numerical value (the likelihood ratio \[LR\]) providing a measure of voice impairment severity for each participant.

Voice recordings will be performed by asking participants to produce a specific speech task with their usual voice intensity, pitch, and quality. The speech task will consist of a sustained emission of a close mid-front unrounded vowel /e/ for at least 5 seconds. Voice recordings will be collected by using a high-definition audio-recorder placed at a distance of 5 cm from the mouth. Voice samples will be recorded in linear PCM format (.wav) at a sampling rate of 44.1 kHz, with 24-bit sample size. Voice analysis will consist of three separate processes: feature extraction, selection and classification. For feature extraction, the investigators will use the OpenSMILE (audEERING GmbH, Germany), dedicated software. Then, the investigators will select and classify voice feature by using SVM algorithm included in Weka.

Eligibility Criteria:
Inclusion Criteria:

* Clinical diagnosis of neurologic disorders

Exclusion Criteria:

* smoking
* bilateral/unilateral hearing loss
* respiratory disorders
* conditions affecting the vocal cords, including nodules.
Ocular Surface Tolerability Study of Prostaglandin Analogues in Patients With Open-Angle Glaucoma or Ocular Hypertension

This study evaluated the ocular surface tolerability of the prostaglandin analogues bimatoprost ophthalmic solution 0.01% (Lumigan® 0.01%), travoprost ophthalmic solution 0.004% (Travatan Z®) and latanoprost ophthalmic solution 0.005% (Xalatan®) in patients previously treated with Xalatan® who have open-angle glaucoma or ocular hypertension.


Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of ocular hypertension or open-angle glaucoma in at least 1 eye requiring treatment with an anti-glaucoma/ocular hypertensive medication
* Best corrected visual acuity score of 20/100 or better in both eyes
* Females on birth control pills must be on same type of pill and dose for at least 3 month

Exclusion Criteria:

* Use of Lumigan® 0.01%/Lumigan® RC, Lumigan®, Travatan® or Travatan Z® within 6 months
* History of or active ocular infection/inflammation (eg, uveitis)
* Punctal plug use
* Required use of ocular medications during the study other than study medication (intermittent use of certain types artificial tears acceptable)
* Intraocular surgery or glaucoma laser surgery in study eye(s) within 3 months
* History of corneal refractive laser surgery (eg, LASIK, LASEK) in study eye(s)
* Planned contact lens wear during study
Effectiveness of VIRTUAL SFCAMINA STUDY

The main objective of this study is to analyse the effectiveness of the VIRTUAL SFCAMINA multicomponent treatment program as coadjuvant of treatmentas- usual (TAU) compared to TAU alone. In this Randomized Controlled Trial (RCT), in addition to evaluating the clinical effects of VIRTUAL SFCAMINA treatment in the short- and long term.

This is a tree-arm RCT focused on the safety and potential effectiveness of the multicomponent program VIRTUAL SFCAMINA as coadjuvant of treatmentas- usual (TAU) vs. TAU alone.

* VIRTUAL SFCAMINA combines multicomponent approach based on Pain Neuroscience Education (PNE), therapeutic exercise, Cognitive Behavioural Therapy (CBT) and Mindfulness training.
* The main hypothesis is that improvement on fatigue of patients with fibromyalgia can be achieved by the direct intervention on mechanisms such as kinesiophobia, fear avoidance and by individualized therapeutic exercise.

Eligibility Criteria:
Inclusion Criteria:

* Meet the Fukuda and Holmes classification criteria for Fatigue Syndrome Chronicle
* Age equal to or greater than 18 years
* Understand and agree to participate in the study
* Sign the informed consent

Exclusion Criteria:

* Terminal clinical conditions or scheduled treatments that may interrupt the study follow-up.
Vitamin D and Screening Colonoscopy or Polyp Surveillance

The investigators will recruit DoD beneficiaries 18 years or older, that have been referred for a screening colonoscopy or polyp surveillance (or had one in the last 2 weeks), and have no previous diagnosis of colorectal cancer. They will have a 25 OH Vitamin D level drawn to determine if there is an association between the level obtained and findings on colonoscopy, or previous findings (if repeating).

DoD beneficiaries age 18 or older will be recruited from the clinics at the Mike O'Callaghan Federal Medical Center (MOFMC). Subjects meeting the inclusion/exclusion criteria will be offered an opportunity to participate:

Screening Visit:

* Obtain signed Informed Consent Document and HIPAA Authorization (research-driven).
* Record: Date of birth, age, gender, race, ethnicity, current email address, height (in inches), weight (in pounds), waist circumference (in inches) measurement, blood pressure, and whether subject is taking or has taken any vitamin D supplement or derivative, and if so, note the dosage, frequency, and duration of therapy.
* Subjects will be told to fast for at least 10 hours prior to Visit 1

Visit 1 (within two weeks of their screening colonoscopy):

-Subjects will have the following research-driven blood test drawn which include: Serum 25-OH vitamin D via 1 venipuncture (5-10 mls, approximately 1-2 teaspoons of blood will be drawn)

Eligibility Criteria:
THIS STUDY IS BEING CONDUCTED AT A MILITARY INSTALLATION. YOU MUST HAVE MILITARY INSURANCE IN ORDER TO PARTICIPATE IN THIS STUDY.

Inclusion:

* DoD beneficiaries 18 years or older
* Referred for a screening colonoscopy or polyp surveillance or had one in the last 2 weeks

Exclusion:

* Previous diagnosis of colorectal cancer, adenomatous polyps, and/or cancer
* Military trainees
* Pregnant women
Functional Follow-up After Endoscopic Calcaneoplasty for Haglund's Deformity

Isokinetic muscle strength test implemented by the Biodex system is a method used for evaluating muscle function that has been applied clinically in the field of sports and rehabilitation medicine. However, information on its application on Haglund's deformity remain insufficient. Therefore, the present study is designed to examine the effectiveness of the muscle strength test using the Biodex system in evaluating the recovery of athletic capacity in patients with Haglund's deformity following endoscopic surgery.

Patients. A retrospective (medical records), level 3 evidence study was designed to evaluate the outcomes of patients who underwent endoscopic surgery for Haglund's deformity. The present study was approved by the Peking University Third Hospital's ethics committee. Written informed consent was obtained from all patients, parents or guardians of the patients prior to the present study. The rights of the patients were protected.

Diagnosis. Patients were designed to be diagnosed based on subjective complaints, combined with clinical and radiological examinations. Radiological measurements for this disease include the Fowler-Phillip angle, calcaneal pith angle, parallel pitch lines, Chauveaux-Liet angle and the X/Y ratio.

Eligibility Criteria:
Inclusion Criteria:

* Patients who underwent endoscopic surgery for Haglund's deformity

Exclusion Criteria:

* None
Retrospective Acute Care Appendectomy Study

The purpose of this retrospective study is to compare perioperative data for subjects who have undergone an emergent or urgent robotic-assisted or laparoscopic appendectomy for acute appendicitis.


Eligibility Criteria:
Inclusion Criteria:

* Subject is 22 years of age or older at time of procedure
* Subject has undergone robotic-assisted or laparoscopic emergent or urgent appendectomy for acute appendicitis between 2018 and 30 days prior to IRB approval

Exclusion Criteria:

* Subject with appendiceal neoplasms
* Subject who underwent a single-port appendectomy
* Subject who was pregnant or breastfeeding at the time of the procedure